Intellia Therapeutics, Inc. (NTLA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 14,245 | 16,627 | 9,111 | |
| Research and development | 97,035 | 108,427 | 123,380 | |
| General and administrative | 27,206 | 29,007 | 30,501 | |
| Total operating expenses | 124,241 | 137,434 | 153,881 | |
| Operating loss | -109,996 | -120,807 | -144,770 | |
| Interest income | 7,402 | 8,603 | 12,122 | |
| Change in fair value of investments, net | 1,339 | -2,125 | -3,064 | |
| Total other income (expense), net | 8,741 | 6,478 | 9,058 | |
| Net loss | -101,255 | -114,329 | -135,712 | |
| Unrealized (loss) gain on marketable securities | -404 | 452 | 4,452 | |
| Comprehensive loss | -101,659 | -113,877 | -131,260 | |
| Net loss per share, basic | -0.98 | -1.1 | -1.34 | |
| Net loss per share, diluted | -0.98 | -1.1 | -1.34 | |
| Weighted average shares outstanding, basic | 103,732,000 | 103,500,000 | 101,002,000 | |
| Weighted average shares outstanding, diluted | 103,732,000 | 103,500,000 | 101,002,000 | |